🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Enovis Corporation ENOV R2K

Healthcare · Medical Devices · United States
https://www.enovis.com

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

READ MORE ›
$22.68
-27.54% 1Y

Market & Price

Market Cap
$1.31B
Current Price
$22.68
High / Low (52W)
$35.94 / $21.46
Beta
1.52

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
5.58
PEG Ratio
3.45
Book Value
$25.66
Price to Book
0.88
P/S
0.57
EV/EBITDA
7.21
Dividend Yield
-

Profitability & Returns

ROCE
-34.75%
ROE
-55.35%
ROA
1.09%
Profit Margin
-49.91%
Op Margin
3.64%
EPS (Latest Qtr)
$-0.15
EPS (TTM)
$-19.89

Balance Sheet & Liquidity

Debt/Equity
0.95
Quick Ratio
0.78
Current Ratio
2.04
Debt
$1.41B
Total Assets
$3.83B
Current Assets
$1.21B
Working Capital
$608.59M

Ownership

Promoter Holding
1.61%
Chg in Prom Hold
-
FII / Inst Holding
119.66%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$2.69B
Total Revenue (TTM)
$2.28B
EBITDA
$372.25M
Free Cash Flow
$206.90M
Operating Cash Flow
$242.84M
Shares Outstanding
57.56M
Gross Margin
61.00%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
12.88%
Profit 5Y
-2,936.97%
Revenue (YoY)
5.40%
Earnings (YoY)
-

PROS

  • Compounding revenue at 12.9% over 5 years.
  • Generates positive free cash flow.

CONS

  • Earnings shrank at -2937.0% CAGR over 5 years.
  • Trading 36.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ENOV Enovis Corporation R2K 22.68 - $1.31B - -34.75% -55.35% 12.88% -2,936.97%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Apr 2020Jul 2020Oct 2020Dec 2020Apr 2021Jul 2021Oct 2021Dec 2021Apr 2022Jul 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Apr 2025Jun 2025Jul 2025Sep 2025Oct 2025Dec 2025Mar 2026Apr 2026
Revenue -----533.27M560.86M524.02M574.93M683.92M908.65M846.52M888.37M816.36M620.36M805.93M828.12M311.08M356.12M359.92M399.06M375.46M395.12M383.81M408.71M406.15M428.50M417.52M516.27M525.16M505.22M558.83M558.83M564.54M564.54M548.91M548.91M575.76M589.15M589.15M
Cost of Revenue -------------------------------226.60M-229.85M-220.00M-226.34M223.67M-
Gross Profit 249.99M239.83M258.06M263.90M267.68M184.58M191.93M171.27M181.59M261.01M376.06M368.14M395.84M348.21M241.09M344.12M354.69M171.28M200.59M197.88M207.92M205.90M215.91M215.82M231.75M235.06M248.36M242.97M297.90M288.88M286.46M332.23M332.23M334.70M334.70M328.91M328.91M349.42M365.49M365.49M
Operating Expenses -------------------------------375.14M-350.78M-337.05M-301.17M356.25M-
Operating Income -60.22M70.12M74.77M-62.17M45.42M35.06M-2.33M41.53M67.86M-46.84M-4.92M61.93M-61.31M-10.35M-16.11M--30.63M5.55M-17.92M--24.97M-14.49M-20.49M-35.01M-44.22M-31.74M-42.91M-46.77M-16.08M-16.80M-8.14M-558.49M48.25M9.24M6.53M
EBITDA -------------------------------23.27M-55.19M--483.66M--425.02M83.16M-
Interest Expense -------------------------------9.19M-9.29M-8.83M-7.51M9.17M-
Pretax Income --------------------------------57.35M--25.65M--566.87M--509.55M634.00K-
Tax Provision --------------------------------1.77M-10.80M-4.00M-9.26M9.04M-
Net Income -38.54M53.39M45.86M-24.54M38.46M31.31M--52.02M-469.23M10.47M------28.64M25.85M-15.07M76.86M-66.61M--23.35M-9.99M-2.88M-72.00M-18.64M-31.52M-55.97M-55.97M-36.74M-36.74M-571.15M-571.15M-520.59M-8.76M-8.76M
Diluted EPS 0.310.310.430.370.110.200.310.260.39-0.39-3.450.08-0.120.03-0.060.100.240.400.560.49-0.040.281.41-1.23-0.71-0.43-0.18-0.05-1.32-0.34-0.58-0.99-0.98-0.64-0.64-9.99-9.99-9.10-0.15-0.15
R&D Expense ----------32.60M16.30M-18.50M14.10M16.80M-19.90M11.04M12.46M-14.84M15.66M15.60M-18.19M18.92M19.90M23.38M23.48M20.49M-28.53M-30.70M-29.74M--31.53M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------1.94B2.19B3.33B1.12B-1.56B1.71B2.11B2.25B
Cost of Revenue -------------693.72M716.42M926.87M902.79M
Gross Profit 185.79M191.41M240.10M1.15B1.31B1.48B1.07B992.38M671.58M729.38M1.40B603.64M-869.38M990.78M1.18B1.35B
Operating Expenses -------------960.04M1.04B1.28B1.36B
Operating Income 39.63M34.37M25.91M140.01M406.39M409.55M265.62M236.85M135.60M151.54M203.61M-66.18M--90.66M-48.37M-103.43M-18.87M
EBITDA -------------241.69M169.73M-481.03M-830.22M
Interest Expense -------------24.05M19.75M57.10M34.82M
Pretax Income --------------2.07M-67.13M-822.92M-1.16B
Tax Provision -------------36.12M-13.29M4.49M22.29M
Net Income 23.80M16.21M4.55M-64.40M178.63M392.10M167.74M128.11M151.09M140.20M-527.65M42.62M--13.29M-33.26M-825.49M-1.18B
Diluted EPS -0.370.10-0.921.543.021.341.041.221.16-3.890.93--0.25-0.61-14.93-20.75
R&D Expense 5.93M6.21M5.71M--------34.27M49.09M60.83M75.33M91.30M120.33M

Compounded Sales Growth

5 Years:12.88%
1 Year:5.40%

Compounded Profit Growth

5 Years:-2,936.97%
1 Year:-

Stock Price Performance

1 Year:-27.54%
6 Months:-25.47%
3 Months:-10.95%
1 Month:+0.84%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Jan 2011Apr 2011Jul 2011Sep 2011Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Mar 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.02B----1.09B6.15B6.60B7.21B6.73B6.34B6.71B6.62B-7.39B7.35B-4.27B4.51B4.72B3.83B
Current Assets -------------------795.02M896.52M1.15B1.21B
Cash & Equivalents 28.76M49.96M60.54M60.54M45.46M64.22M64.45M75.11M482.45M311.30M305.45M197.47M208.81M262.02M77.15M-109.63M97.07M-24.30M36.19M48.17M36.39M
Inventory -------------------426.64M468.83M547.12M584.38M
Receivables -------------------267.38M291.48M407.03M442.79M
Total Liabilities --805.71M----899.27M3.99B3.86B3.86B3.48B3.25B2.98B3.14B-3.90B3.76B-823.45M1.09B2.15B2.34B
Current Liabilities --191.51M----240.04M1.18B1.38B1.28B1.12B1.06B1.10B1.20B-857.31M811.66M-565.20M369.61M529.00M598.47M
Long Term Debt --72.50M----101.52M1.69B1.46B1.53B1.41B1.29B1.06B1.19B-2.28B2.20B-40.00M466.16M1.31B1.26B
Total Debt -------------------334.82M536.42M1.40B1.38B
Total Equity 181.38M216.82M216.37M----189.28M1.91B2.51B3.15B3.07B2.90B3.50B3.27B3.49B3.44B3.54B-3.45B3.42B2.56B1.49B
Shares Outstanding -------------------54.23M54.60M55.88M57.19M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 38.70M61.97M57.15M174.02M362.17M385.76M303.81M246.97M218.77M226.37M130.95M301.94M--55.86M134.99M113.50M217.29M
Investing Cash Flow -12.46M-40.41M-69.97M-1.94B-474.97M-1.03B-246.96M-81.99M89.88M-167.85M-1.63B-175.08M--176.39M-242.47M-955.47M-179.37M
Financing Cash Flow -5.42M-8.04M32.74M2.18B-45.05M650.05M-131.27M-145.22M-280.45M-47.15M1.37B-131.65M--465.13M127.80M846.82M-52.40M
Capital Expenditure -11.01M-12.53M-14.79M-83.59M-71.48M-84.46M-69.88M-63.25M-68.77M-69.65M-125.40M-114.78M--105.45M-122.22M-180.71M-197.38M
Free Cash Flow 27.70M49.44M42.37M90.43M290.69M301.30M233.94M183.72M150.00M156.72M5.55M187.15M--161.31M12.77M-67.21M19.92M
Net Change in Cash --------------697.38M20.32M4.85M-14.48M
Share Buybacks ----0027.37M20.81M0200.00M00-004.77M3.50M
Dividends Paid -205.00K00-------------

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------34.7%33.3%42.1%53.9%-55.6%58.0%56.0%59.8%
Operating Margin % --------7.0%6.9%6.1%-5.9%--5.8%-2.8%-4.9%-0.8%
Net Margin % --------7.8%6.4%-15.9%3.8%--0.9%-1.9%-39.2%-52.7%
ROE % 11.0%7.5%2.4%-3.4%7.1%12.5%5.5%4.4%4.3%4.3%-15.3%1.2%--0.4%-1.0%-32.2%-79.5%
ROCE % -4.1%3.1%2.8%7.8%6.9%4.7%4.5%2.4%2.8%3.1%-1.0%--2.4%-1.2%-2.5%-0.6%

Shareholding Pattern

Insiders
1.61%
Institutions
119.66%
Public Float
121.62%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 17.26% 9.94M $225.36M
2 American Century Companies Inc 8.28% 4.77M $108.16M
3 Vanguard Portfolio Management LLC 6.62% 3.81M $86.38M
4 Vanguard Capital Management LLC 4.43% 2.55M $57.89M
5 Dimensional Fund Advisors LP 4.42% 2.55M $57.74M
6 Rubric Capital Management LP 4.26% 2.45M $55.64M
7 Davenport & Co LLC 4.24% 2.44M $55.30M
8 State Street Corporation 4.17% 2.40M $54.48M
9 Paradigm Capital Management 3.09% 1.78M $40.30M
10 Hood River Capital Management LLC 3.05% 1.76M $39.84M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENOV

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks